Korro Bio, Inc.
Close on Oct 19, 2026
- Market cap
- $156.98M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | – | $-1.07 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 12, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | After market close | $1.10M | $-1.92 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | Before market open | $1.50M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | After market close | $2.60M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 18, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 26, 2024 | After market close | – | – | – |
Press releases
Announcements Korro Bio filed with the SEC
Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121
Other events · EX-99.1 to Form 8-K
Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Material agreement · Results of operations · Unregistered share sale · EX-99.1 to Form 8-K
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Other events · EX-99.1 to Form 8-K
May 2026 Corporate Presentation Exhibit 99.2
Other events · EX-99.2 to Form 8-K
Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Korro Announces Oversubscribed $85 Million Private Placement
Material agreement · Results of operations · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
KRRO-121: A Potential First-in-Class Treatment for Ammonia Control January 27th, 2026 Exhibit 99.1
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Korro Reports Third Quarter Financial Results,
Material agreement · Results of operations · Exit or restructuring costs · Executive or director change · EX-99.1 to Form 8-K
Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Korro Reports First Quarter 2025 Financial Results and Provides Business Updates
Results of operations · Exit or restructuring costs · EX-99.1 to Form 8-K
Korro Reports Full Year 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board
Other events · EX-99.1 to Form 8-K
Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Korro Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Korro Announces $70 Million Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress
Results of operations · EX-99.1 to Form 8-K
Edit the Message, Rewrite the Future January 2024 1
Other events · EX-99.1 to Form 8-K
UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million
Material agreement · Acquisition or disposition completed · Results of operations · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
2023, we completed the business combination with the privately held Delaware corporation, Korro Bio, Inc., or Legacy Korro, in accordance with the terms of the Agreement and Plan of Merger dated as of July 14, 2023, or the Merger Agreement,
Material agreement · Acquisition or disposition completed · Results of operations · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
2023, we completed the business combination with the privately held Delaware corporation, Korro Bio, Inc., or Legacy Korro, in accordance with the terms of the Agreement and Plan of Merger dated as of July 14, 2023, or the Merger Agreement,
Material agreement · Acquisition or disposition completed · Results of operations · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Korro Bio and Frequency Therapeutics Announce Merger Agreement
Regulation FD disclosure · EX-99.1 to Form 8-K
(c) 2023 Korro Bio, Inc. 1
Regulation FD disclosure · EX-99.2 to Form 8-K
Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Frequency Therapeutics Provides Business Updates and Fourth Quarter
Results of operations · EX-99 to Form 8-K
Pioneering a New Category in
Results of operations · Exit or restructuring costs · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Pioneering a New Category in
Regulation FD disclosure · EX-99.1 to Form 8-K
Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Frequency Therapeutics Corporate Presentation September 2022
Regulation FD disclosure · EX-99.1 to Form 8-K
Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Frequency Therapeutics Corporate Presentation April 2022
Exit or restructuring costs · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Frequency Therapeutics Corporate Presentation March 2022
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K